HANSE lung cancer screening starts in summer
Registration is open: The lung cancer screening study HANSE (Holistic implementation study Assessing a Northern German interdisciplinary lung cancer Screening Effort) starts to recruit participants. Physicians from the three participating clinics (LungenClinic Grosshansdorf, University Medical Center Schleswig-Holstein (Lübeck Campus) and Hannover Medical School) are looking for former or active smokers aged 55 to 79. Those interested in a lung check can register via the study website.
As part of HANSE, 12,000 subjects at risk of lung cancer will be screened by low-dose CT. In addition, lung function will be tested. Blood and exhaled breath will be used to investigate whether early detection can be further improved by comparing diseased and healthy individuals. People with abnormal findings can report directly to one of the three participating clinics for clarification.
If lung cancer is detected at an early stage, the chances of curing it are significantly higher. The study is intended to demonstrate that an effective lung cancer screening program can be implemented in Germany. This is particularly important because “lung cancer often causes no symptoms in its early stages, which is why more than half of the patients are not diagnosed until they reach a metastasized stage,” says study head of HANSE, Prof. Dr. Jens-Vogel-Claussen of Hannover Medical School (DZL site BREATH).
ARCN project leaders involved are Dr. Sabine Bohnet from UKSH (Lübeck Campus) and Prof. Dr. Martin Reck from LungenClinic Grosshansdorf. Dr. Eckart von Hirschhausen serves as patron the the study. HANSE is funded by the Clinical Trial Board of the DZL and by AstraZeneca.